Straight to the Point
with Ankylosing Spondylitis


In this activity, two of Australia's leading rheumatologists - Prof Paul Bird and A/Prof Ana Ananda - meet to discuss the efficacy, safety, and role of interleukin-17 (IL-17) inhibitors in ankylosing spondylitis (AS) patients naïve to, or with prior experience to, biologics.

Learning outcomes

By the end of this activity, participants will be able to:

  1. Discuss the recommendations from treatment guidelines regarding the initiation of IL-17 inhibitors for patients with AS
  2. Summarise the efficacy and safety of IL-17 inhibitors in patients with AS
  3. Outline the importance of IL-17 inhibitors in the treatment of AS patients who are inadequately responding to TNFIs
  4. Discuss the benefits of initiating IL-17 inhibitors in biologic-naïve AS patients


This education has been designed for the RACP CPD Program for the 2023-25 triennium. Upon completion of this activity you may claim 1 hour of Category 1 Educational Activity learning in the RACP’s MyCPD program

Other healthcare professionals can still enrol and complete this course. You will receive a certificate upon completion.


If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.